Click here for slides on this topic


Intensive therapy

Treatment for diabetes in which blood glucose is kept as close to normal as possible through a combination of diabetes therapies, both oral and injectable.
The following content matched the glossary term: Intensive therapy

ADVANCE-ON: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Top

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;[epub ahead of print]. doi: 10.1056/NEJMoa1407963.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Top

Neugebauer R, Fireman B, Roy JA, O’Connor PJ. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care. 2013;36:3510-3516.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of VADT. Saremi A, Bahn G, Reaven PD; for the VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390-2392. Cross-sectional data from the Veterans Affairs Diabetes Trial (VADT) showed that participants with coronary artery or abdominal aortic calcification had an increased prevalence of cardiovascular disease, including peripheral artery disease and coronary artery disease.

Health benefits of gastric bypass surgery after 6 years

Top

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122-1131. This prospective study by Adams and colleagues explored the weight loss and cardiometabolic benefits of Roux-en-Y gastric bypass (RYGB) among severely obese patients over 6 years of follow-up.

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

NDEI.org Expert Commentary ACCORD BP Trial Henry Ginsberg

Top

Expert commentary from Henry Ginsberg, MD on post-hoc analysis of ACCORD BP trial examining the potential interaction between obesity and intensive blood pressure treatment on CVD outcomes.

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Top

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585. The blood-pressure (BP) arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study evaluated the effects of intensive BP-control on cardiovascular disease (CVD) events among high-risk subjects with type 2 diabetes.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Intensive therapy Slides Found: 53
UKPDS Results of Intensive Therapy: Sulfonylurea and Insulin
UKPDS Results of Intensive Therapy: Metformin vs Conventional Therapy
DCCT/EDIC: Incidence of Any Cardiovascular Disease Outcome
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Steno-2: Percentage of Patients at Treatment Goals at End of Study
Steno-2: Effect of Multifactorial Intervention on Mortality in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on CV Events in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on Various CV Events in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on Diabetic Complications
Steno-2: Effect of Multifactorial Intervention on Diabetic Neuropathies
ACCORD: Study Design
ACCORD: Results
ADVANCE: Death from Any Cause
ADVANCE: Primary Endpoints
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
VADT: Comparing Intensive With Standard Glucose Therapy, Secondary Outcomes
VADT: Comparing Intensive With Standard Glucose Therapy, Change in Median A1C
VADT: Comparing Intensive With Standard Glucose Therapy, Adverse Events
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
Meta-Analysis: Conclusion
ACCORD: A1C and Mortality Risk
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD: Death from Any Cause
Weight Gain from Type 2 Diabetes Treatment in ACCORD
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
ACP Guidelines: Inpatient Hyperglycemia Management with IIT
ADVANCE-ON Type 2 Diabetes Study Baseline Characteristics Slide | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes BP Lowering Slide | NDEI
ADVANCE-ON Type 2 Diabetes Secondary Outcomes BP Lowering Slide | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
ADVANCE-ON Type 2 Diabetes Intensive Control Macrovascular Slide | NDEI
ADVANCE-ON Type 2 Diabetes Intensive Control Design | NDEI
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
ACCORD BP Post-hoc Analysis: Primary Outcome by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis: Design
ACCORD BP Post-hoc Analysis: Secondary Outcomes by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis:Outcomes by Treatment Group, Waist-to-Height Quartiles